GoodRx Holdings, Inc. - Class A Common Stock (GDRX)
4.6700
-0.1800 (-3.71%)
GoodRx Holdings Inc is a healthcare technology company that provides consumers with affordable access to prescription medications
Through its platform, GoodRx offers price comparisons for prescription drugs at various pharmacies, enabling users to find the lowest available prices. In addition to its pricing tools, the company offers discount coupons, telehealth services, and health information resources, ultimately striving to improve transparency and cost-effectiveness in the prescription drug market. Its services aim to empower consumers in making informed choices about their healthcare needs.
Healthcare tech company GoodRx (NASDAQGDRX) missed Wall Street’s revenue expectations in Q4 CY2024, with sales flat year on year at $198.6 million. On the other hand, the company expects next quarter’s revenue to be around $203 million, close to analysts’ estimates. Its non-GAAP profit of $0.09 per share was in line with analysts’ consensus estimates.
GoodRx Holdings, Inc. (Nasdaq: GDRX) ("we," "us," "our," “GoodRx,” or the “Company”), the leading prescription savings platform in the U.S., has released its financial results for the fourth quarter and full year of 2024.
GoodRx (Nasdaq: GDRX), the leading medication savings platform in the U.S., today announced its drug savings platform residing with Amazon Web Services (AWS) has earned certified status for 2025 by HITRUST for information security. This milestone underscores GoodRx’s dedication to safeguarding data and maintaining specific standards of cybersecurity in healthcare.
Personal health and wellness is one of the many secular tailwinds for healthcare companies. But speed bumps have persisted in the wake of COVID-19 as players destocked inventories in 2023 and 2024.
This has weighed on the returns lately as the industry has pulled back by 1.7% over the past six months. This performance is a noticeable divergence from the S&P 500’s 9% return.
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the industry’s returns -
over the past six months, healthcare stocks have collectively shed 1.7%. This drop is a stark contrast from the S&P 500’s 9% gain.
GoodRx (Nasdaq: GDRX), the leading prescription savings platform in the U.S., today announced that Christopher A. McGinnis has been appointed as Chief Financial Officer, effective February 4, 2025. Chris brings 30 years of extensive financial experience across the healthcare industry to his new role.
GoodRx Holdings, Inc. (Nasdaq: GDRX) (“GoodRx” or the “Company”), the leading prescription savings platform in the U.S., today announced it will release its fourth quarter and full year 2024 financial results before U.S. markets open on Thursday, February 27, 2025. GoodRx management will also hold a conference call and webcast that morning at 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) to discuss the results and the Company’s business outlook.
GoodRx Holdings, Inc. (Nasdaq: GDRX) ("we," "us," "our," “GoodRx” or the “Company”), the leading prescription savings platform in the U.S., today announced that Scott Wagner has joined its Board of Directors, effective January 21, 2025. Mr. Wagner, who recently led GoodRx as its Interim Chief Executive Officer from April 2023 to January 2025, has been appointed as Co-Chair of the Board and will serve alongside existing Co-Chair Trevor Bezdek.
GoodRx (Nasdaq: GDRX), the leading prescription savings platform in the U.S., today announced it is offering free online healthcare provider visits to California residents impacted by the wildfires devastating Los Angeles County. Starting today, Angelenos can use the code LA-GOODRX-CARE to be seen by a licensed medical provider on GoodRx Care for a variety of conditions.
GoodRx (Nasdaq: GDRX), the leading prescription savings platform in the U.S., today announced a new GoodRx for Pets experience that provides a more affordable and convenient way for Americans to access pet medications. Through GoodRx for Pets, pet owners can find savings and have pet medications delivered right to their door. GoodRx for Pets provides a seamless experience for pet owners, combining convenience, affordability, and accessibility in one place.
GoodRx Holdings, Inc. (Nasdaq: GDRX) (“GoodRx” or the “Company”), the leading prescription savings platform in the U.S., today announced that executives from the Company will participate in a fireside chat at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 15, 2025 at 9:45 a.m. Pacific Time (12:45 p.m. Eastern Time).
GoodRx (Nasdaq: GDRX), the leading prescription savings platform in the U.S., today revealed startling healthcare disparities in its new report, “Endocrinologist Deserts: A Critical Healthcare Gap for Millions in the U.S.” With nearly 70% of U.S. counties lacking an endocrinologist, the report paints a stark picture of the barriers millions of Americans face in managing life-threatening conditions like diabetes.
GoodRx Holdings, Inc. (NASDAQGDRX), the leading prescription savings platform in the U.S., today announced that Wendy Barnes has been appointed as President and Chief Executive Officer, effective January 1, 2025. Wendy brings more than 30 years of leadership experience across the pharmacy and medical benefit industry to her new role.
GoodRx's latest research shows surging demand for weight loss medications like Wegovy and Zepbound, despite high costs and limited insurance coverage, with consumers overspending $200 million in 2024.
GoodRx (Nasdaq: GDRX), the leading prescription savings platform in the U.S., today released a new Weight Loss Medications Tracker that provides an inside look at fill trends and spending patterns for weight loss medications across the U.S. The company found that limited insurance coverage and high out-of-pocket costs aren’t slowing down interest in popular drugs used for weight loss such as Mounjaro, Ozempic, Wegovy, and Zepbound. In fact, some of these popular drugs have seen fills more than double in just the past year. What’s more, GoodRx’s research shows that Americans overspent by at least $200 million in 2024 by paying the full retail price for their weight loss medications and not leveraging savings available on GoodRx, showcasing an astounding willingness to access these medications at any cost.
NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against GoodRx Holdings, Inc. (NASDAQGDRX) on behalf of long-term stockholders following a class action complaint that was filed against GoodRx on April 22, 2024 with a Class Period from September 23, 2020, to November 8, 2022. Our investigation concerns whether the board of directors of GoodRx have breached their fiduciary duties to the company.
